For instance, we compared the kinase profile of > 3‐fold significantly regulated kinases of five AD patients with the KRAS mutations G13D, G12A, G12C, G12V and KRAS amplifications to nine AD patients without driver mutations and did not observe significant differences between the two cohorts (Figure 6E). This evidence concerns the gene KRAS and Alzheimer disease.